- £351.34m
- £359.10m
- £0.11m
REG - Avacta Group PLC - Q1 2026 Business Update
AnnouncementRCS - Avacta Group PLC - Avacta Announces Science Day 2026
AnnouncementREG - AIM - AIM Notice - 07/04/2026
AnnouncementREG - Avacta Group PLC - First patient treated in Phase 1 trial of AVA6103
AnnouncementREG - Avacta Group PLC - Result of Oversubscribed Fundraise
AnnouncementREG - Avacta Group PLC - Issue of Equity
AnnouncementRCS - Avacta Group PLC - Presentations of pre|CISION® Platform Candidates
AnnouncementREG - Avacta Group PLC - Phase 1 study opening for AVA6103
AnnouncementREG - Avacta Group PLC - PreCISION payload delivery advantage over ADC
AnnouncementRCS - Avacta Group PLC - Avacta to Participate in Conference March 2026
AnnouncementREG - Avacta Group PLC - Appointment of CSO
AnnouncementREG - Avacta Group PLC - Faridoxorubicin Program Clinical Updates
AnnouncementREG - Avacta Group PLC - FDA Clearance of IND Application for AVA6103
AnnouncementREG - Avacta Group PLC - Year-end trading update
AnnouncementREG - Avacta Group PLC - Appointment of Nominated Adviser & TVR
AnnouncementRCS - Avacta Group PLC - Avacta reports new AVA6103 pharmacology data
AnnouncementREG - Avacta Group PLC - Faridoxorubicin Phase 1b SGC data
AnnouncementREG - Avacta Group PLC - Preliminary Data in Faridoxorubicin Phase 1b Trial
AnnouncementREG - AIM - AIM Notice - 03/11/2025
Announcement